Finally, the presence of CYP3A4 inhibitors or CYP3A4 strong affinity substrates was the most important parameter driving changes in medical expenditures, ED visits, and hospitalizations, both at baseline and following the addition of iclepertin; this observation remained true in the schizophrenia population. This evidence concerns the gene CYP3A4 and schizophrenia.